Avanos Medical, Inc. operates as a medical technology company that focuses on delivering medical device solutions to improve patients' quality of life in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps and Game Ready cold and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain relieving therapies, such as Coolief pain relief therapy. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
IPO Year: 2014
Exchange: NYSE
Website: avanos.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/25/2023 | Overweight → Sector Weight | KeyBanc Capital Markets | |
| 5/22/2023 | $31.00 | Buy | CL King |
| 2/24/2022 | $47.00 → $41.00 | Overweight | Keybanc |
| 1/7/2022 | $37.00 → $36.00 | Underweight | Morgan Stanley |
| 8/4/2021 | $45.00 → $41.00 | Underweight | Morgan Stanley |
| 8/4/2021 | $60.00 → $45.00 | Overweight → Equal-Weight | Stephens |
| 8/4/2021 | $55.00 → $47.00 | Overweight | Keybanc |
10-Q - AVANOS MEDICAL, INC. (0001606498) (Filer)
8-K - AVANOS MEDICAL, INC. (0001606498) (Filer)
8-K - AVANOS MEDICAL, INC. (0001606498) (Filer)
8-K/A - AVANOS MEDICAL, INC. (0001606498) (Filer)
8-K - AVANOS MEDICAL, INC. (0001606498) (Filer)
8-K - AVANOS MEDICAL, INC. (0001606498) (Filer)
8-K/A - AVANOS MEDICAL, INC. (0001606498) (Filer)
8-K - AVANOS MEDICAL, INC. (0001606498) (Filer)
DEFA14A - AVANOS MEDICAL, INC. (0001606498) (Filer)
DEF 14A - AVANOS MEDICAL, INC. (0001606498) (Filer)
4 - AVANOS MEDICAL, INC. (0001606498) (Issuer)
ALPHARETTA, Ga., May 6, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today reported first quarter 2025 financial results. "In my first couple of weeks at Avanos, I've noticed that the transformation efforts made around the portfolio, the organizational structure and cost management have positioned us well to accelerate our growth profile," said David Pacitti, Avanos's recently appointed Chief Executive Officer. Pacitti continued, "I really like the energy and strategic focus we have right now, which can be leveraged for more consistent execution, to identify more go-t
ALPHARETTA, Ga., April 28, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) will webcast its conference call discussing financial results and business highlights for the first quarter 2025 on Tuesday, May 6 at 9 a.m., ET. The company will issue a news release detailing its results before the market opens that same day. The conference call will be hosted by Dave Pacitti, chief executive officer, Jason Pickett, interim chief financial officer, Scott Galovan, senior vice president, strategy and corporate development, and Gary Blackford, Avanos board chairman. To instantly jo
ZAVENTEM, Belgium, April 2, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) a global medical technology company, today announced that it will take direct responsibility for the sales and distribution of its MIC-KEY enteral feeding products in the United Kingdom, effective 25 July 2025. This strategic move reflects Avanos' commitment to prioritizing customer needs, enhancing product availability into the future, and providing a seamless experience for healthcare providers and patients. For the past 29 years, Vygon UK, a leading supplier of surgical and medical devices has
ALPHARETTA, Ga., March 17, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS), a leading medical technology company, today announced the appointment of David Pacitti as its new chief executive officer, effective April 14, 2025. Pacitti joins Avanos with a distinguished career in the healthcare sector, most recently serving as president of Siemens Medical Solutions USA, Inc. and Head of the Americas, Siemens Healthineers. In this capacity, he played a pivotal role in driving strategic growth and operational excellence while leading the marketing, sales, service, and support
ALPHARETTA, Ga., Feb. 26, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today reported fourth quarter and full-year 2024 results. "We are pleased with our fourth quarter results, which delivered 5% organic growth and continued execution on each of our transformation initiative priorities," said Michael Greiner, Avanos's interim chief executive officer. Greiner continued, "For the full year, we generated $83 million of free cash flow and $108 million of adjusted EBITDA. We currently have net debt of approximately $20 million. We believe our strong financial position wil
ALPHARETTA, Ga., Feb. 19, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) will webcast its conference call discussing financial results and business highlights for the fourth quarter and full year 2024 on Wednesday, Feb. 26 at 9 a.m., ET. The company will issue a news release detailing its results before the market opens that same day. The conference call will be hosted by Michael Greiner, interim chief executive officer and Scott Galovan, senior vice president, strategy and corporate development. To instantly join the conference call by phone, use the following link to
ALPHARETTA, Ga., Jan. 6, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today announced that Michael Greiner, interim chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Monday, Jan. 13, at approximately 3:45 p.m. PST. A webcast of the conference presentation will be available on the Investors section of the Avanos Medical website and will be archived on that site. About Avanos Medical, Inc. Avanos Medical, Inc. (NYSE:AVNS) is a medical technology company focused on delivering clinically superior m
ALPHARETTA, Ga., Nov. 12, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today announced that Michael Greiner, interim chief executive officer, will participate in an analyst-led fireside chat at the Stifel 2024 Healthcare Conference at the Lotte New York Palace in New York on Tuesday, Nov. 19 at approximately 3:35 p.m. ET. A webcast of the conference presentation will be available on the Investors section of the Avanos Medical website and will be archived on that site. About Avanos Medical, Inc. Avanos Medical, Inc. (NYSE:AVNS) is a medical technology company focused o
ALPHARETTA, Ga., Nov. 11, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) announced today that the Centers for Medicare and Medicaid Services (CMS) has issued its final Medicare Hospital Outpatient Prospective Payment System (OPPS) and Medicare Ambulatory Surgical Center (ASC) Payment System rule for 2025. This rule, effective Jan. 1, 2025, implements the Non-Opioids Prevent Addiction in the Nation (NOPAIN) Act that mandates separate Medicare payment for qualifying non-opioid drugs and devices. The NOPAIN Act, passed as part of the Consolidated Appropriation Act of 2023,
ALPHARETTA, Ga., Nov. 8, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today announced that Michael Greiner, interim chief executive officer, will participate in a fireside chat at the UBS 2024 Healthcare Conference on Tues., Nov. 12 at approximately 2:45 p.m. Pacific Time. A webcast of the conference presentation will be available on the Investors section of the Avanos Medical website and will be archived on that site. About Avanos Medical, Inc. Avanos Medical, Inc. (NYSE:AVNS) is a medical technology company focused on delivering clinically superior medical device so
3 - AVANOS MEDICAL, INC. (0001606498) (Issuer)
3/A - AVANOS MEDICAL, INC. (0001606498) (Issuer)
3 - AVANOS MEDICAL, INC. (0001606498) (Issuer)
4 - AVANOS MEDICAL, INC. (0001606498) (Issuer)
4 - AVANOS MEDICAL, INC. (0001606498) (Issuer)
4 - AVANOS MEDICAL, INC. (0001606498) (Issuer)
4 - AVANOS MEDICAL, INC. (0001606498) (Issuer)
4 - AVANOS MEDICAL, INC. (0001606498) (Issuer)
4 - AVANOS MEDICAL, INC. (0001606498) (Issuer)
4 - AVANOS MEDICAL, INC. (0001606498) (Issuer)
KeyBanc Capital Markets downgraded Avanos Medical from Overweight to Sector Weight
CL King initiated coverage of Avanos Medical with a rating of Buy and set a new price target of $31.00
Keybanc reiterated coverage of Avanos Medical with a rating of Overweight and set a new price target of $41.00 from $47.00 previously
Morgan Stanley reiterated coverage of Avanos Medical with a rating of Underweight and set a new price target of $36.00 from $37.00 previously
Morgan Stanley reiterated coverage of Avanos Medical with a rating of Underweight and set a new price target of $41.00 from $45.00 previously
Stephens downgraded Avanos Medical from Overweight to Equal-Weight and set a new price target of $45.00 from $60.00 previously
Keybanc reiterated coverage of Avanos Medical with a rating of Overweight and set a new price target of $47.00 from $55.00 previously
ALPHARETTA, Ga., May 6, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today reported first quarter 2025 financial results. "In my first couple of weeks at Avanos, I've noticed that the transformation efforts made around the portfolio, the organizational structure and cost management have positioned us well to accelerate our growth profile," said David Pacitti, Avanos's recently appointed Chief Executive Officer. Pacitti continued, "I really like the energy and strategic focus we have right now, which can be leveraged for more consistent execution, to identify more go-t
ALPHARETTA, Ga., April 28, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) will webcast its conference call discussing financial results and business highlights for the first quarter 2025 on Tuesday, May 6 at 9 a.m., ET. The company will issue a news release detailing its results before the market opens that same day. The conference call will be hosted by Dave Pacitti, chief executive officer, Jason Pickett, interim chief financial officer, Scott Galovan, senior vice president, strategy and corporate development, and Gary Blackford, Avanos board chairman. To instantly jo
ALPHARETTA, Ga., Feb. 26, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today reported fourth quarter and full-year 2024 results. "We are pleased with our fourth quarter results, which delivered 5% organic growth and continued execution on each of our transformation initiative priorities," said Michael Greiner, Avanos's interim chief executive officer. Greiner continued, "For the full year, we generated $83 million of free cash flow and $108 million of adjusted EBITDA. We currently have net debt of approximately $20 million. We believe our strong financial position wil
ALPHARETTA, Ga., Feb. 19, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) will webcast its conference call discussing financial results and business highlights for the fourth quarter and full year 2024 on Wednesday, Feb. 26 at 9 a.m., ET. The company will issue a news release detailing its results before the market opens that same day. The conference call will be hosted by Michael Greiner, interim chief executive officer and Scott Galovan, senior vice president, strategy and corporate development. To instantly join the conference call by phone, use the following link to
ALPHARETTA, Ga., Oct. 30, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today reported third quarter 2024 financial results and announced the retirement of its CEO, Joe Woody. Gary Blackford, Avanos Board Chairman, noted, "Joe has decided to retire after leading Avanos for the past seven years. Joe has agreed to assist the Company in the transition of leadership, and will continue to consult with the Company through April of next year. Avanos is better positioned financially and organizationally today to achieve its longer-term value creation goals because of Joe's lea
ALPHARETTA, Ga., Oct. 23, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) will webcast its conference call discussing financial results and business highlights for the third quarter 2024 on Wednesday, Oct. 30 at 9 a.m., ET. The company will issue a news release detailing its results before the market opens that same day. The conference call will be hosted by Joe Woody, chief executive officer, and Michael Greiner, senior vice president, chief financial officer, and chief transformation officer. To join the live conference call, dial 1-800-836-8184 in the United States. A
ALPHARETTA, Ga., July 31, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today reported second quarter 2024 financial results. "We are pleased with our second quarter results and the cumulative progress we have made at the mid-year point," said Joe Woody, Avanos's chief executive officer. Woody continued, "Digestive Health continues to lead in delivering high-single digit growth while Pain Management and Recovery performance is improving with quarter-over-quarter sequential growth, and we are seeing meaningful progress on our other transformation objectives, all of whic
ALPHARETTA, Ga., July 24, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) will webcast its conference call discussing financial results and business highlights for the second quarter 2024 on Wednesday, July 31 at 9 a.m., ET. The company will issue a news release detailing its results before the market opens that same day. The conference call will be hosted by Joe Woody, chief executive officer, and Michael Greiner, senior vice president, chief financial officer, and chief transformation officer. To join the live conference call, dial 1-800-836-8184 in the United States.
ALPHARETTA, Ga., May 2, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today reported first quarter 2024 financial results. "As we begin the second year of our three-year transformation initiative, we are pleased with our first quarter results," said Joe Woody, Avanos's chief executive officer. Woody added, "We continue to make progress on our long-term margin expansion targets, are delivering on our Digestive Health growth objectives and have made improvements in our Pain Management and Recovery franchise that will support our mid-single digit growth in the back half o
ALPHARETTA, Ga., April 25, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) will webcast its conference call discussing financial results and business highlights for the first quarter 2024 on Thursday, May 2 at 9 a.m., ET. The company will issue a news release detailing its results before the market opens that same day. The conference call will be hosted by Joe Woody, chief executive officer, and Michael Greiner, senior vice president, chief financial officer, and chief transformation officer. To join the live conference call, dial 1-800-836-8184 in the United States. A s
ALPHARETTA, Ga., March 17, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS), a leading medical technology company, today announced the appointment of David Pacitti as its new chief executive officer, effective April 14, 2025. Pacitti joins Avanos with a distinguished career in the healthcare sector, most recently serving as president of Siemens Medical Solutions USA, Inc. and Head of the Americas, Siemens Healthineers. In this capacity, he played a pivotal role in driving strategic growth and operational excellence while leading the marketing, sales, service, and support
ALPHARETTA, Ga., July 1, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today announced that Indrani Franchini has been appointed as a new independent member of the Avanos board of directors. "We are excited to welcome Indrani Franchini to the Avanos board," remarked Gary Blackford, Avanos board chair. "Her experience with a broad range of global companies will be invaluable to Avanos as we pursue our vision of getting patients back to the things that matter." "Avanos is committed to addressing some of today's most important healthcare needs and I am thrilled to join it
ALPHARETTA, Ga., May 13, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today announced that Sigfrido (Sig) Delgado has been appointed senior vice president, integrated supply chain. In this role, Delgado will lead the teams focused on implementing continuous improvements within the Company's end-to-end supply chain capabilities worldwide. Delgado joins Avanos from Jabil Healthcare, the industry's largest global provider of healthcare manufacturing solutions, where he most recently served as vice president of its global medical technology business. His background includ
ALPHARETTA, Ga., March 6, 2023 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today announced that Dr. Lisa Egbuonu-Davis, currently vice president, medical innovations, for DH Diagnostics, LLC, an affiliate of Danaher Corporation, has been appointed as a new independent member of the Avanos board of directors and will serve as a member of the compliance and governance committees. "We are pleased and excited to welcome Lisa Egbuonu-Davis to the Avanos board," commented Gary Blackford, Avanos board chair. "Her deep strategic and operational expertise in the healthcare sector
ALPHARETTA, Ga., Nov. 14, 2022 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today announced that Sudhakar Varshney has been appointed senior vice president, global supply chain & procurement. In this role, Varshney will lead a multinational team of more than 2,500 employees to drive the development and execution of the Company's supply chain capabilities worldwide. Varshney joins Avanos from Antylia Scientific, a bioprocessing and life sciences organization, where he was senior vice president, global operations. His background includes more than 20 years in manufacturing,
ALPHARETTA, Ga., July 12, 2021 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today announced that Moji James has been appointed senior vice president & general counsel. In this role, James will oversee the Company's legal, government relations and global security functions. During her more than 25 years practicing law, James has supported the development and commercialization of innovative drugs, biologics and vaccines. She most recently served as executive vice president, chief legal and compliance officer of Tmunity Therapeutics, a biotherapeutics company, where she was
SC 13G - AVANOS MEDICAL, INC. (0001606498) (Subject)
SC 13G/A - AVANOS MEDICAL, INC. (0001606498) (Subject)
SC 13G/A - AVANOS MEDICAL, INC. (0001606498) (Subject)
SC 13G/A - AVANOS MEDICAL, INC. (0001606498) (Subject)
SC 13G/A - AVANOS MEDICAL, INC. (0001606498) (Subject)
SC 13G/A - AVANOS MEDICAL, INC. (0001606498) (Subject)
SC 13G/A - AVANOS MEDICAL, INC. (0001606498) (Subject)
SC 13G - AVANOS MEDICAL, INC. (0001606498) (Subject)
SC 13G/A - AVANOS MEDICAL, INC. (0001606498) (Subject)
SC 13G/A - AVANOS MEDICAL, INC. (0001606498) (Subject)